Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.


Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
10 2020
Historique:
received: 10 05 2020
revised: 26 05 2020
accepted: 29 07 2020
pubmed: 20 8 2020
medline: 12 1 2021
entrez: 20 8 2020
Statut: ppublish

Résumé

Evidence for endoscopic balloon dilation of small intestinal strictures in Crohn's disease (CD) using balloon-assisted enteroscopy is scarce. To evaluate endoscopic balloon dilation for the treatment of small intestinal CD strictures using balloon-assisted enteroscopy. Citations in Embase, MEDLINE, and Cochrane were systematically reviewed. In a meta-analysis of 18 studies with 463 patients and 1189 endoscopic balloon dilations, technical success was defined as the ability to dilate a stricture. Individual data were also obtained on 218 patients to identify outcome-relevant risk factors. In the pooled per-study analysis, technical success rate of endoscopic balloon dilation was 94.9%, resulting in short-term clinical efficacy in 82.3% of patients. Major complications occurred in 5.3% of patients. During follow-up, 48.3% of patients reported symptom recurrence, 38.8% were re-dilated and 27.4% proceeded to surgery. On the per-patient-based multivariable analysis, that patients with disease activity in the small intestine had lower short-term clinical efficacy (odds ratio 0.32; 95% confidence interval 0.14-0.73, P = 0.007). Patients with concomitant active disease in the small and/or large intestine had an increased risk to proceed toward surgery (hazard ratio 1.85; 95% confidence interval 1.09-3.13, P = 0.02 and hazard ratio 1.77; 95% confidence interval 1.34-2.34, P < 0.001). Balloon-assisted enteroscopy for dilatation of CD-associated small intestinal strictures has high short-term technical and clinical efficacy and low complication rates. However, up to two-thirds of patients need re-dilation or surgery.

Sections du résumé

BACKGROUND
Evidence for endoscopic balloon dilation of small intestinal strictures in Crohn's disease (CD) using balloon-assisted enteroscopy is scarce.
AIM
To evaluate endoscopic balloon dilation for the treatment of small intestinal CD strictures using balloon-assisted enteroscopy.
METHODS
Citations in Embase, MEDLINE, and Cochrane were systematically reviewed. In a meta-analysis of 18 studies with 463 patients and 1189 endoscopic balloon dilations, technical success was defined as the ability to dilate a stricture. Individual data were also obtained on 218 patients to identify outcome-relevant risk factors.
RESULTS
In the pooled per-study analysis, technical success rate of endoscopic balloon dilation was 94.9%, resulting in short-term clinical efficacy in 82.3% of patients. Major complications occurred in 5.3% of patients. During follow-up, 48.3% of patients reported symptom recurrence, 38.8% were re-dilated and 27.4% proceeded to surgery. On the per-patient-based multivariable analysis, that patients with disease activity in the small intestine had lower short-term clinical efficacy (odds ratio 0.32; 95% confidence interval 0.14-0.73, P = 0.007). Patients with concomitant active disease in the small and/or large intestine had an increased risk to proceed toward surgery (hazard ratio 1.85; 95% confidence interval 1.09-3.13, P = 0.02 and hazard ratio 1.77; 95% confidence interval 1.34-2.34, P < 0.001).
CONCLUSIONS
Balloon-assisted enteroscopy for dilatation of CD-associated small intestinal strictures has high short-term technical and clinical efficacy and low complication rates. However, up to two-thirds of patients need re-dilation or surgery.

Identifiants

pubmed: 32813282
doi: 10.1111/apt.16049
pmc: PMC8052861
mid: NIHMS1688941
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1104-1116

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK097948
Pays : United States
Organisme : NIH HHS
ID : P30DK097948 Pilot
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK123233
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK083251
Pays : United States
Organisme : NIH HHS
ID : K08DK110415
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK110415
Pays : United States
Organisme : NIH HHS
ID : T32DK083251
Pays : United States

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Endoscopy. 2007 Feb;39 Suppl 1:E276
pubmed: 17957636
Gastrointest Endosc. 2007 Sep;66(3 Suppl):S108-12
pubmed: 17709019
Fibrogenesis Tissue Repair. 2014 Mar 29;7(1):5
pubmed: 24678903
Gastrointest Endosc. 2001 Feb;53(2):216-20
pubmed: 11174299
Inflamm Bowel Dis. 2017 Jan;23(1):133-142
pubmed: 28002130
Intern Med. 2017 Sep 1;56(17):2245-2252
pubmed: 28794359
Endoscopy. 2008 Dec;40(12):974-8
pubmed: 19065477
J Crohns Colitis. 2020 Feb 10;14(2):155-168
pubmed: 31742338
Dig Endosc. 2010 Jul;22(3):200-4
pubmed: 20642609
Gut. 2019 Jun;68(6):1115-1126
pubmed: 30944110
Gastrointest Endosc. 2009 Nov;70(5):1030-6
pubmed: 19640518
Gut. 2018 Jan;67(1):53-60
pubmed: 28119352
Inflamm Bowel Dis. 2016 Feb;22(2):380-6
pubmed: 26535767
PLoS One. 2015 Dec 14;10(12):e0144872
pubmed: 26658675
J Crohns Colitis. 2017 Feb;11(2):135-149
pubmed: 27660342
Gastroenterology. 2008 Oct;135(4):1106-13
pubmed: 18692056
Gastrointest Endosc. 2009 Jan;69(1):84-93
pubmed: 19111689
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
Therap Adv Gastroenterol. 2014 May;7(3):108-14
pubmed: 24790641
VideoGIE. 2016 Aug 30;1(2):32-33
pubmed: 29905207
Aliment Pharmacol Ther. 2018 Aug;48(3):347-357
pubmed: 29920726
Inflamm Bowel Dis. 2002 Jul;8(4):244-50
pubmed: 12131607
J Crohns Colitis. 2016 Aug;10(8):873-85
pubmed: 26928961
Eur J Gastroenterol Hepatol. 2007 Jul;19(7):529-34
pubmed: 17556897
Dig Endosc. 2014 Jul;26(4):545-51
pubmed: 24528293
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2514-2522.e8
pubmed: 30503966
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Gastrointest Endosc. 2017 Dec;86(6):997-1005
pubmed: 28652176
J Gastroenterol. 2016 Oct;51(10):939-48
pubmed: 26831355
Gastroenterology. 2017 Feb;152(2):340-350.e6
pubmed: 27720839
Gastroenterology. 2010 Oct;139(4):1147-55
pubmed: 20637205
J Crohns Colitis. 2018 Mar 28;12(4):394-401
pubmed: 29194463
Endosc Int Open. 2014 Dec;2(4):E201-6
pubmed: 26135093

Auteurs

Arne Bokemeyer (A)

Münster, Germany.

Lei Kou (L)

Cleveland, OH, USA.

Rocio Lopez (R)

Cleveland, OH, USA.

James F Bena (JF)

Cleveland, OH, USA.

Sara El Ouali (S)

Cleveland, OH, USA.

Ren Mao (R)

Cleveland, OH, USA.
Guangzhou, China.

Satya Kurada (S)

Cleveland, OH, USA.

Amit Bhatt (A)

Cleveland, OH, USA.

Torsten Beyna (T)

Düsseldorf, Germany.

Brendan Halloran (B)

Edmonton, AB, Canada.

Matthew Reeson (M)

Edmonton, AB, Canada.

Shuhei Hosomi (S)

Osaka, Japan.

Masahiro Kishi (M)

Chikushino, Japan.

Fumihito Hirai (F)

Chikushino, Japan.
Fukuoka, Japan.

Naoki Ohmiya (N)

Toyoake, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH